



Value creation: M&A, partnerships, collaborations, new sources of capital, and shifting portfolios

Cautious optimism in 2024

The economic and geopolitical climate will likely continue to impact decision-making in 2024.

Over the past year, life sciences and medical technology (medtech) companies have been managing inflation, rising interest rates (which can curtail access to capital), and slower economic growth. However, in 2024, inflation seems to be lessening, rates appear to be stabilizing, if not dropping, and growth is likely to be moderate—setting up a cautious, but still active mergers and acquisitions (M&A) and capital environment.

M&A activity collectively in biopharma, platforms, medtech, and diagnostics was brighter than many expected in 2023—with 254 M&A deals and US\$209.8 billion in total announced value—eclipsing 2022 figures of US\$143.5 billion.¹ The overall sector fared better

than the overall M&A market where US and global total deal value across all sectors fell 11% compared to 2022.²

Valuations grew for life sciences companies in most stages of their life cycles over the past year. In 2024, pharma companies will be finetuning strategies to create top-line value with strategic acquisitions, while also planning for long-term bottom-line improvements, including divestitures and cost reductions.

While glucagon-like peptide 1 (GLP-1) obesity drugs have been a boon for pharmaceutical companies, their rise, along with macroeconomic headwinds, are creating uncertainty for medtech valuations, which were down US\$300 million in 2023. However, fundamentals are strong, and medtech leaders are bullish on growth in 2024, given the improving supply chain situation.

M&A: Creating momentum

Pharma’s megadeals put buying power on display

A primary driver of strength in 2023 were large/mega cap pharmaceutical companies with undeployed capital (figure 1).³ Dealmakers are paying healthy premiums for assets with high commercial potential with oncology being the strongest therapeutic area attracting investment.⁴ The top 10 megadeals closed in 2023 were each worth more than US\$4 billion, led by multibillion dollar deals by Pfizer/Seagen (US\$43 billion) and Bristol Myers Squibb/Karuna Therapeutics (US\$14 billion).⁵ A number of the leading acquisitions involved medicines either nearing regulatory approvals or in advanced testing.⁶

In 2024, companies should continue to expect regulatory scrutiny for a variety of investment activities. To facilitate the Pfizer/Seagen deal and address antitrust regulators’ concerns, Pfizer agreed to donate the rights of royalties from sales of cancer

drug Bavencio to the American Association for Cancer Research.⁷ At the end of 2023, the US Federal Trade Commission (FTC) also settled its Amgen/Horizon Therapeutics acquisition challenge.⁸

“Blockbuster and mega blockbuster product opportunities are getting the most attention in M&A, and that will likely continue over the course of 2024. Once the best late stage assets are picked up—we should start to see more partnering and M&A for earlier stage assets, as there is a lot of interest in accessing new product growth opportunities.”

—Daniel O’Connell, CEO, Acumen

Figure 1. 2023 M&A deal characteristics in life sciences by buyer groups

	Small/mid-cap	Large/mega cap	Private equity	Private strategic
Pharmaceuticals	Pre-clinical oncology; milestone payments are common, contingent on commercialization + regulatory	Acquisitions of companies with approved oncology assets, particularly in the ADC space	Driven largely by one acquisition in the antibiotics space seen as a platform for further growth	Acquisitions of approved and late-stage rare disease assets
MedTech & diagnostic	Geographic expansion in orthopedics and consolidate play in spine	Tuck-in deals across various therapeutic areas, including neurovascular, diabetes, and spine	Minimal activity	Large transaction in interventional urology; otherwise, limited tuck-in activity
CRO/CDMO/supplier	Strength in cell and gene manufacturing and supportive AI tools for biological drug development	Considerable investments in products used in protein-based drug therapy development	Significant capital deployed into both CROs and CDMOs	Small asset acquisitions of life sciences suppliers

Over the next year, some big pharma companies will continue to look to M&A to plug portfolio gaps as a result of loss of exclusivity (LoE) across various therapeutic areas. In particular, late-stage

development/early-stage commercial assets—that could contribute material revenue growth over the next few years—are expected to be attractive targets.⁹


Pharma M&A strategy highlight: Offsetting loss of exclusivity (LOE) with new acquisitions

Successful acquisitions may offset LOE patents for large pharmaceutical companies. Between 2022 and 2030, pharma companies will likely lose more than US\$200 billion in revenue from the anticipated tectonic patent cliff.¹⁰

Pfizer, which faces US\$17 billion in potential LOE between 2025 and 2030 and significant undeployed cash on their balance sheet from their COVID-19

portfolio, closed the largest M&A deal for biopharma in 2023. In its US\$43 billion deal to acquire Seagen, Pfizer gained a market leader in antibody-drug conjugate technology to strengthen its position in oncology.¹¹ Pfizer projects an increase of US\$3.1 billion in 2024 for top-line growth directly from the deal as well as bottom-line improvements over the long-term plan (figure 2).¹²

Figure 2. Pfizer's long-term plan to strengthen top-line growth after acquiring Seagen (illustrative)



Source: Pfizer, "Pfizer Invests \$43 Billion to Battle Cancer," March 13, 2023

Pharma's near-term divestitures/cost reductions

The immediate term may look bleaker as multiple pharma giants announce divestitures and cost reductions^{13–14}—including some work force cuts. Pipeline assets may be sold to other big pharma companies, while others sell to smaller companies and retain minority stakes. Given a few high-profile successes, this trend is likely to continue in 2024.¹⁵

As a result, freed-up capital may be deployed into accretive transactions.¹⁶ While cautiously optimistic for 2024,¹⁷ many experts expect that deal volume and value will pick up over the next year.¹⁸

Medtech returns to growth after 2023 divestitures

While pharma M&A activity was a bright spot in 2023, medtech and diagnostics M&A was not as strong. Over the past year, activity declined across M&A and venture, but the decline was not unexpected as medtech companies focused primarily on portfolio rationalization, divestitures, and cost transformation.¹⁹ According to Deloitte US research, divestitures are being used to reduce debt and improve capital structures, generating improved balance sheets.²⁰

Total deal value decreased nearly 45% year-over-year to US\$13.5 billion, while deal volume actually accelerated. Some stakeholders continue to be optimistic about deal volume in 2024,²¹ with companies targeting smaller deals in the US\$200 million to US\$800 million range.²²

Regulators are also scrutinizing medtech deals. A protracted battle with regulators led to Illumina divesting its interest in Grail at the end of 2023.²³ Medtronic scrapped a US\$738 million deal to buy South Korean-based EOfFlow, an insulin patch-pump maker.²⁴

In 2024, M&A is poised for a positive inflection point for improved activity as strategics and private equity alike re-enter the acquisition fold. M&A activity

from medtech mega-cap players is likely to include high-growth small/mid-cap companies as well as emerging companies with interesting technology that could disrupt existing businesses.²³ Optimism is also being propelled by digital therapeutics and at-home diagnostics, growing use of biometric diagnostics, and speed to market.²⁴

Private equity: Megadeals and tougher fundraising environment

More going private

More sponsor-backed companies may decide to go private instead of languishing at a below-IPO stock price in 2024.²⁷ Private equity (PE) investments in life sciences peaked in 2021 with 695 PE transactions totaling US\$127.5 billion.²⁸ The space includes biotech and medical device companies as well as providers of related tools and services, like contract research organizations (CROs).²⁹

Volume of P&E deals soars for life sciences suppliers

PE continues its interest in life sciences suppliers, deploying more than US\$10 billion in capital into contract development and manufacturing organizations (CDMOs). M&A deal value across CROs/CDMOs/suppliers has jumped nearly 85% year over year to US\$28.3 billion, while volume is up 50%. CDMOs are expected to attract more PE interest in 2024 and beyond as the need for highly specialized manufacturing facilities continues to increase.³⁰

Tougher fundraising environment

Notable PE megadeals in 2023 included the US\$7.1 billion privatization of biopharma CRO Syneos Health and the acquisition of veterinary drug maker Dechra Pharmaceuticals by Sweden's EQT for about US\$6.1 billion, one of the biggest UK PE deals in 2023.³¹ However, while EQT has been very successful in fundraising over the recent years, they are looking for new sources of capital, like private wealth, in a tougher overall fundraising environment.³²

Venture capital: Billion-dollar fundraises amidst biotech challenges

Life sciences dealmaking in the startup space continues to decelerate after experiencing record highs in 2021 but is still above pre-pandemic levels. Venture capital (VC) remains active and resilient compared to many other fields,³³ and six funds that closed in the second half of 2023 now have more than US\$6 billion to deploy into new investments in 2024.³⁴ A notable development to kick off startup investing in early 2024 is a US\$3 billion raise by biotech creator Arch—a multibillion dollar deal that comes roughly two years after raising a similar amount.³⁵

The pace of biotech IPOs stalled in 2023 with only 19 drugmakers pricing initial share sales.³⁶ Many experts are cautiously optimistic for 2024, and some anticipate a roller coaster year.³⁷ Six IPOs kicked off 2024, however, including a US\$93.8 million deal for gene editing startup Metagenomi—one of the rare biotech companies to go public recently without a drug already in clinical trials.³⁸

Biotech also hit a 10-year peak for bankruptcies with 18 companies filing for protection, preceded by 8 in 2022, and the next highest year in 2014, with 7.³⁹ Three companies already filed in early 2024, Humanigen, Athertsys,⁴⁰ and Invitae (which is preparing for sale).⁴¹

Partnerships and collaborations: Expanding capabilities in tech and R&D

Integrating AI/ML

Representing a broader industry transition, there is a growing focus on precision medicine and personalized therapies that leverage advanced technologies, like artificial intelligence (AI) and machine learning (ML).⁴² The promise of AI is expected to drive additional new partnerships in 2024 as large companies look to obtain new technological capabilities, secure industry talent, and drive competitive advantage.

Several AI-based drug development partnerships were signed in Q3 and Q4 of 2023.⁴³ The Verge Genomics/Alexion (AstraZeneca Rare Disease) collaboration is worth US\$42 million up front—consisting of a fee, equity, and near-term payments—and the potential

for US\$840 million in downstream royalties.⁴⁴ The collaboration will use CONVERGE®, Verge's AI-enabled approach for identifying novel drug targets for rare neurodegenerative and neuromuscular diseases.⁴⁵

AbbVie made an upfront payment of US\$30 million with potential milestone payments and royalties to AI/ML company BigHat Biosciences to commence an antibody research collaboration in oncology and neuroscience.⁴⁶

Medtech companies continue to explore strategic collaborations across the health care ecosystem to leverage AI. GE HealthCare recently signed a US\$44M contract with BARDA to develop AI-augmented ultrasound technology. A partnership was also formed with Mayo Clinic for innovation in medical imaging and theranostics—to enhance precision diagnosis and improve patient treatment using multi-modal data, AI, and digital health solutions.

Medtronic partnered with NVIDIA and Cosmo Pharmaceuticals to integrate NVIDIA's AI technologies into its GI Genius™ intelligent endoscopy module. They've also partnered with IBM Watson Health to develop AI tools for the diagnosis and treatment of heart disease.

R&D picking up steam and a multibillion-dollar deal

LoE is also driving market leaders to various types of partnerships. The top 20 highest value licensing, collaboration, and partnerships deals in 2023 were each worth at least US\$1 billion—the total reaching about US\$75 billion already by Q3 2023—with the largest transaction having a potential value of US\$22 billion.⁴⁷

Half the deals in the top 20 list for 2023 were around oncology assets and technology platforms, followed by cardiology and neurological diseases. In the booming area of antibody-drug conjugates, Merck and Co. and Daiichi Sankyo came together in a US\$5.5 billion deal that has a potential lifetime value of US\$22 billion.⁴⁸ The deal was the largest in a decade and unusual in that it involved a US\$4 billion upfront cash payment. Daiichi Sankyo will retain rights for Japan, and the two giants will collaborate globally to develop candidates in other markets.⁴⁹

In 2024, biotech companies with strong late-stage pipelines are ripe for acquisition and seeking exits.⁵⁰ But many small to mid-cap biotech companies facing a cash crunch are also looking to acquisitions, while a record number go bankrupt.⁵¹ Partnerships are a growing trend and may be an alternative to M&A to boost values in 2024.

New sources of capital: Partnerships and strategic collaborations as alternatives to M&A for biotech

Tighter capital markets for small and midsize biotech companies in 2023 required many companies to find alternative ways of financing, including cutting costs and private investment. IPOs and public markets cooled, and venture funding investment was lower than in 2022 but still above pre-pandemic levels. At BIO Europe in late 2023, pharma companies made clear that substantial funding will be available for early-stage investment. However, biotech companies are still cautious and uncertain about how readily accessible funds will be.⁵²

Addressing challenges with creativity and resourcefulness

Biotech companies are increasingly looking at partnerships and other creative collaborations as an alternative, or precursor, to M&A. The length of time to get regulatory clearances can be especially challenging, and many small to midsize biotechs have shorter cash runways for 2024 than in the past. In addition, prior to M&A, alliances and joint ventures may be used to demonstrate the viability of the business proposition, leaving regulators more comfortable with the arrangement.⁵³

Reaping the benefits of partnerships and strategic collaborations

Some substantial benefits may be gained via joint efforts to acquire or have access to:

- New assets, like innovative science, platforms, and patents

- New capabilities and resources, like expertise, manufacturing, commercialization for large-scale indications, established infrastructures globally, and advanced technologies, e.g., AI
- New markets and patient populations
- Ecosystem-wide synergies and gap funding through public/private partnerships
- A trusted relationship that builds a pathway to future M&A

To find a symbiotic collaborator, companies need to first critically assess fit, complementary skills/resources, and the values/benefits that bring each partner to the table. But even when fit is determined and the deal has been structured and negotiated, the real work begins.

“Small to midsize biotechs may underestimate the resources and effort a partnership will take. When you have a limited resource base to start with, there are not a lot of departments to hand these things off to. Also, companies shouldn’t underestimate the work it will take to build trust—and to stay true to the principles that were the basis for partnering in the first place,”

—Renee Aguiar-Lucander, CEO, Calliditas Therapeutics



Accessing new markets and new patient populations

For its first ever partnership, Calliditas Therapeutics set their sights on the world’s second largest pharmaceutical market, China, in 2019. Calliditas entered into a licensing agreement with Everest Medicines to develop and commercialize its treatment for IgA nephropathy in Greater China and Singapore to address a huge patient need.⁵⁴ Chronic immune-mediated kidney disease is a major cause of kidney failure in China and other Asian countries, although considered a rare disease in the United States and Europe.

The partnership required Calliditas to remain agile—as clinical trial plans were disrupted by the pandemic—and work on the relationship differences between its own Scandinavian culture and that of China. For example, CEO Renee Aguiar-Lucander says her Swedish colleagues had a reluctance to say “no” when something could not be done. In many cultures, saying no may be viewed as problematic or impolite.⁵⁴


New sources of capital: Public/private partnerships for biomedical innovation

With tightened funding in the private sector, some companies find that government funding can become gap funding. COVID-19 provided an exemplary model for how governments can work with collaborators to advance care and treatment for all diseases, and, contrary to popular belief, government and nongovernmental institutional investment in biomedical areas does not reduce private spending on R&D.⁵⁶

Beyond the pandemic, governments may continue to move disruptive ecosystem-wide solutions for biomedical innovation by:


- Prioritizing patients and communities in the innovation pipeline
- Leveraging the full continuum of relationships and partners
- Supporting funding and collaboration infrastructure for last-mile innovations⁵⁷

Figure 3. Three synergy strategies for governments and collaborators



A government’s ability to subsidize research and development in areas of unmet need may serve as a mechanism to drive research to the last-mile pipeline (figure 3).⁵⁸ Two mechanisms that some governments have used in the past could be key to de-risking high-risk research areas:

- **Push incentives** that reduce the cost of development by offering financial, tax, and technical incentives regardless of anticipated failure in the market



- **Pull incentives** that reward developments already considered relevant in the market and scientifically viable by helping ensure developers' financial viability into the future, even in inefficient markets⁵⁹

Breakthrough biomedical innovations are not only possible but probable with government investment in the right infrastructure and incentives.⁶⁰

New sources of capital: Medtech VCs launch new funds

After a downturn, VC investing in medtech started garnering renewed interest in mid-2023. Neuralink, Elon Musk's brain-reading startup (via implantable

chips), and Beta Bionics, a low-touch automated insulin delivery system for diabetics, started an upturn with nine-figure deals.⁶¹

More selective investing

Venture capital investors are searching for visionary medtech founders to make more selective investments in 2024, and the digital health market could have promising opportunities for real innovators.⁶² The most active category of medtech VC funding has been cardiovascular surgical devices. From 2020 through Q3 2023, Qiming Venture Partners is the leading medtech venture investor and Medtronic, the top acquirer (figure 4)⁶³

Figure 4. Top medtech acquirers and VC investors from 2020 to 30 September 2023

Investor	Deal count	Investor type
Medtronic	5	Corporation
Boston Scientific	4	Corporation
Thermo Fisher Scientific	3	Corporation
Laborie Medical Technologies	3	PE-backed company
Philips	3	Corporation
Ottobock	3	PE-backed company

Investor	Deal count	pre-seed/ seed	Early-stage VC	Late- stageVC	Venture growth	Investor type
Qiming	49	0	25	22	2	VC
Hingshan	39	0	16	17	4	VC
Enterprise Ireland	34	3	7	14	10	VC
YuanBio Venture Capital	33	0	18	13	2	VC
European Innovation Council Fund	33	1	6	21	3	VC
Khosla Ventures	30	3	3	18	3	VC
Lilly Aisa Ventures	27	2	17	7	1	CVC
SOSV	27	6	2	18	1	VC
ShangBay Capital	26	3	14	7	2	VC
Johnson & Johnson Innovation - JJDC	24	0	7	13	4	CVC

Source: Pitchbook, Geography: Global

At the end of 2023, experts estimate the average cash balance at large medtech companies stood at approximately US\$5 billion, up US\$1.5 billion since early 2019.⁶⁴ Potential areas of M&A interest include mechanical circulatory support; transcatheter mitral and tricuspid valve repair and replacement; pulsed field ablation; peripheral vascular solutions; interventional devices to treat venous thromboembolism; and diabetes technology.⁶⁵ The left atrial appendage (LLA) closure market for reducing stroke is valued at US\$1.4 billion and captured the interest of two companies, Johnson & Johnson and Medtronic, in separate deals. The LAA market is projected to reach US\$6 billion by 2030.⁶⁶

Tapping medtech giants' venture arms

Visionary startup founders may find opportunities through medtech giants' venture arms, like Boston Scientific and Johnson & Johnson.⁶⁷ For example, Johnson & Johnson Development Corporation (JJDC), Johnson & Johnson's venture arm, has innovation teams for early-stage startups around the globe—including in Shanghai, Boston, San Francisco, and London⁶⁸—with its most notable exits including 23andMe, Nevro, and Grail.⁶⁹

Intuitive Surgical's venture arm added a US\$150 million fund in late 2023 bringing their total assets under management to US\$250 million in 2024 across three investment areas:⁷⁰ Improving health care access and coordination; precision diagnostics and interventions; and secure, enriched digital health ecosystems.⁷¹

In addition to access and affordability, new business models that focus on early-detection and preventive care are drawing investment.⁷² Also promising are digital health companies that focus on diagnostics to improve patient outcomes.⁷³

New sources of capital: Medtech funding through government initiatives

The road to digital health and medtech innovation is being supported through many diverse economic initiatives with a growing focus on making medical services and devices for consumers more affordable and accessible.

Some examples of recent government biomedical or medtech initiatives around the globe include:

United States—The US administration recently designated 31 tech hubs across the country with 13 dedicated to either biomedical or medtech innovation. Some examples are the Greater Philadelphia Region Precision Medicine Tech Hub and Elevate Quantum Colorado.⁷⁴ Quantum computing has the potential to train AI in medical diagnostics more efficiently.⁷⁵

Canada—Over CAD\$2.1 million through PrairiesCan will help enable Alberta's health and medical technology sector to ramp up the commercialization of human mobility and home health innovations.⁷⁶

Scotland—The Medical Device Manufacturing Centre (MDMC) has been awarded £3.35 million of additional funding from Scottish Enterprise to develop medical device innovation and improve the industry's sustainability.⁷⁷

United Kingdom—The UK government is providing the National Health Service (NHS) with £21 million across 64 trusts to deploy new AI tools for the diagnosis and treatment of patients.⁷⁸

Australia—The Australian government has set up an AUD\$50 million fund for a combined AUD\$115 million with Brandon BioCatalyst & ANDHealth towards a BioMedTech Incubator program.⁷⁹

Shifting portfolios: Value creation in a new era of blockbuster drugs

Some companies are doubling down on oncology and specialty diseases, while others are committing to more prevalent chronic disease areas. In oncology, the Pfizer/Seagen deal escalated the excitement around antibody drug conjugates (ADCs), setting off a deal-making frenzy to snap up ADC assets and technologies.⁸⁰

Merck, Daiichi Sankyo, BMS, and AbbVie all began making moves to access and/or expand their position in ADCs by the end of 2023. Japan's Daiichi Sankyo is also investing US\$1.08 billion to create an "international innovation center" by 2030 in Germany and will equip the site to develop and manufacture future ADCs.⁸¹ The size of ADC investments reflects a growing and increasingly valuable drug class that some proponents hope may eventually replace some forms of standard chemotherapy.⁸²

Momentum is expected to continue, as the approach—using antibodies' specificity for targeted delivery of potent cytotoxic drugs—comes of age.⁸³ In 2024, deals from Johnson & Johnson/Ambryx and Roche/MediLink Therapeutics kicked off the year as well as smaller acquisitions and licensing.⁸⁴ Pharma and biotech interest is also attracting venture financing to ADC start-ups.⁸⁵

In parallel, the market is rewarding those focused on more prevalent disease areas with the excitement over and growth of GLP-1 obesity drugs—a trend not seen in recent years. Those companies not active in either are finding themselves needing to explain their portfolio and scientific strategies.

At the 2024 J.P. Morgan Healthcare conference in January, Novartis found itself needing to explain the choice to double down on radioligand therapies (RLT), a platform where the company believes it can continue its established leadership for the long-term. Like ADCs, RLTs act like a guided missile but use a ligand to target cancer cells and kill them with a therapeutic radioisotope.⁸⁶ Novartis believes RLTs deliver better efficacy while producing less adverse events than ADCs.⁸⁷


Rise of the GLP-1 weight loss boom, valuations, and market projections

Drugs originally developed to treat type 2 diabetes are now being formulated as popular weight loss drugs. Eli Lilly manufactures Mounjaro for diabetes (approved 2022) and its newly approved version for weight loss, Zepbound.⁸⁸ Novo Nordisk is also an obesity drug market leader with Wegovy (approved 2021) and Ozempic (approved 2022).⁸⁹

Among biopharma market leaders, Novo Nordisk and Eli Lilly have some of the highest valuations due to long-term growth expectations and category leadership in metabolic diseases—including diabetes and obesity as the most prevalent. By the end of Q1 2024, Novo Nordisk's market capitalization reached a high of US\$572.92 billion, rising from US\$88.53 billion in late November 2016. Eli Lilly had a market cap high of US\$740.30 billion, rising from US\$74.1 billion in November 2016.⁹⁰

The positive sentiment associated with the potential of their GLP-1 drugs is bringing Eli Lilly and Novo Nordisk valuations on par with or greater than some leading tech growth stocks, like Tesla, as well as being disproportionate to the S&P 500 Pharma Index (figure 5). Analysts predict this upward trajectory to continue.

Figure 5. Stock performance of Eli Lilly and Novo Nordisk vs. S&P 500 and S&P 500 Pharma, Q2 2021 to Q1 2024



Source: Deloitte analysis

Experts say the treatment of obesity is on the verge of heading into mainstream primary care—comparable to the growth of hypertensive drugs that ballooned into a US\$30 billion market in the 1990s.⁹¹ The rising prevalence of lifestyle-related diseases is expected to continue to drive up overall GLP-1 agonist drug market projections. By 2030, the potential market is being priced anywhere from US\$37 billion to more than US\$100 billion.⁹² While no one knows exactly how big it might be,⁹³ the surge is being driven by treatments for obesity and diabetes—a potential market of 30 million people in the United States alone by the end of the decade.⁹⁴

In addition, GLP-1 agonists are being heralded as Science’s “2023 Breakthrough of the Year” as potential new uses for the drugs emerge.⁹⁵ GLP-1s are showing promise for cardiovascular disease and investigations are underway for drug addiction, Alzheimer’s, and Parkinson’s diseases. These new uses may increase insurance coverage down the line.⁹⁶



Growing high-quality concentrated revenue

Growing high-quality concentrated revenue, like Eli Lilly has achieved in the past four to six quarters, demonstrates an enviable road to value creation. Eli Lilly is making a long-term commitment in the obesity drug market with multiple obesity drug candidates in mid- and late-stage clinical development. At the end of 2023, the company also announced a multi-year partnership with startup Fauna Bio for obesity research with animal genomes, adding to the signs of a decade-long commitment to the market.⁹⁷ The result is Eli Lilly becoming the world’s largest drugmaker by market cap—with 12% top-line growth and 20% bottom-line growth.

Addressing lack of reimbursement

Beyond the ability to meet the surging demand, another headwind to be navigated in 2024 and beyond is likely to be the lack of access and broader insurance coverage for obesity drugs. In the United States, lack of reimbursement for obesity treatments under government health care programs essentially makes these medications unaffordable.⁹⁸ Programs for low-income Americans do cover the drugs in some areas, but access is fragmented.⁹⁹

Millions of older Americans on US Medicare cannot access the drugs, mostly because obesity drugs were originally classed as cosmetic in 2003; US lawmakers plan to push for a change in 2024.¹⁰⁰ If 10% of Medicare beneficiaries with obesity used a GLP-1, the annual cost to Medicare is estimated to be between US\$13.6 billion and US\$26.8 billion. But the total annual medical cost in the United States for obese adults averages US\$1,861 higher than medical costs for people with healthy weight.¹⁰¹

Public and private payers could learn from guidelines in several EU countries, such as Norway, the Netherlands, Poland, and Italy.¹⁰² These countries have reimbursement policies that may demonstrate a pathway to affordable coverage in the United States—slowing the progression of the disease. For example, some European coverage models deploy effective, but lower-cost medications for patients with lower BMI that do not meet the criteria for “obesity” but whose health could still benefit from treatment.¹⁰³

Competition in weight loss market heats up, and digital health support services grow

Competitors and lower cost formulations that may also have potentially fewer side effects may be new entrants to the market. New products will need to distinguish themselves by clear advantages, and pharma companies have begun investigating:

- Novel molecular targets with alternate routes of administration

- Extended treatment intervals
- New double- and triple-agonist mechanisms¹⁰⁴

Competition is already ramping up as Pfizer and Amgen are expected to release new data in 2024,¹⁰⁵ and several drugs in development may become attractive for acquisition. In late December 2023, Roche took over unlisted obesity drug developer Carmot Therapeutics in a US\$2.7 billion upfront deal.¹⁰⁶

Some smaller pharma companies are developing agents with novel mechanisms of action (MOAs), including Switzerland-based Aphaia Pharma and Japan's Shionogi.¹⁰⁷ Implications are expected for ingredients and support services. VCs are eyeing opportunities in weight care and management via both telemedicine and coaching as consumer interest soars (figure 6).¹⁰⁸

Figure 6. Notable global VC deals for weight loss startups


Name	Close Date	Deal Size	Valuation	Deal Type	Location
Lark	10/13/2021	\$100	\$800.0	Late Stage	Mountain View
Calibrate	11/08/2022	\$37.5	\$365.0	Early Stage	New York
Zoe	11/01/2022	\$34.8	\$264.3	Late Stage	London
Nutrisense	06/28/2022	\$25.0	\$95.0	Early Stage	Chicago
Form Health	01/13/2023	\$22.9	\$6209	Early Stage	Boston
BooHee	11/21/2021	\$15.6	\$310.0	Late Stage	Shanghai
January AI	08/15/2022	\$13.0	\$28.8	Late Stage	Menlo Park
Nourish	01/20/2023	\$9.3	\$40.3	Seed	Austin
Intelliheath	02/15/2022	\$8.5	\$58.7	Seed	San Francisco
Veri	06/01/2022	\$7.9	\$12.5	Early Stage	Helsinki

Source: Pitchbook

GLP-1 proofing portfolios

While the rise of GLP-1 has created tremendous opportunities in obesity and obesity-related assets, some market leaders are also looking to GLP-1 proof their portfolios, flocking to “GLP-1-resistant”

therapeutic areas like rare diseases, neurology, and oncology. Medtech companies may search for assets that are not impacted by GLP-1s or assets for which an increase in longevity could mean an increase in utilization.¹⁰⁹



Contacts

Chris Caruso

Partner
Deloitte United States
ccaruso@deloitte.com

Teresa Leste

Principal
Deloitte Monitor
tleste@deloitte.com

Prateep Menon

Principal
Deloitte United States
pmenon@deloitte.com

Michael Van der boom

Partner
Deloitte Switzerland
mvanderboom@deloitte.ch

Interested in learning more about **Value creation: M&A, partnerships, collaborations, new sources of capital, and shifting portfolios** and its impact on global life sciences? Check out these Deloitte publications:

[Measuring value from digital transformation](#)

[Biopharma's digital supply chain](#)

[Life Sciences M&A Trends](#)

[Health plans' financial performance](#)

Endnotes

Value creation: M&A, partnerships, collaborations, new sources of capital, and shifting portfolios

1. Chris Dokomajilar, "Healthcare and Life Sciences Deal and Funding Review of 2023," DealForma, 25 January 2024.
2. Matthew W. Abbott, "M&A at a Glance (2023 Year-End Roundup)," Paul Weiss, accessed 3, April 2024.
3. Deloitte, "Life sciences M&A 2023 trends," 2024.
4. Raveena Bhambra, "Top 20 biopharma deals of 2023," Biopharma Dealmakers, accessed 3, April 2024.
5. Eric Sagonowsky, "The top 10 biopharma M&A deals of 2023," Fierce Pharma, accessed 3 April 2024.
6. Gwendolyn Wu, "5 questions facing emerging biotech in 2024," BioPharma Dive, accessed 3 April 2024.
7. Pfizer, "Pfizer Completes Acquisition of Seagen," press release, 14 December 2023.
8. Federal Trade Commission, "FTC Approves Final Order Settling Horizon Therapeutics Acquisition Challenge," press release, 14 December 2023.
9. Chris Dokomajilar, "Healthcare and Life Sciences Deal and Funding Review of 2023."
10. Ibid.
11. Pfizer, "Pfizer Invests \$43B to Battle Cancer," 13 March 2023.
12. Ibid.
13. Deloitte, "Life sciences M&A 2023 trends," 2024.
14. Neil Versel, "Biopharma Layoff Tracker 2024: Carisma, Omega, Xilio and More Cut Staff," BioSpace, 2 April 2024.
15. Deloitte, "Life sciences M&A 2023 trends," 2024.
16. Ibid.
17. Gwendolyn Wu, "5 questions facing emerging biotech in 2024."
18. Madeline Shi, "Meet the 5 most active PE investors in life sciences," PitchBook, 3 December 2023.
19. Deloitte, "Life sciences M&A 2023 trends."
20. Ibid.
21. "Medtech M&A outlook in 2024," Eversheds Sutherland, accessed 3 April 2024.
22. Deloitte, "Life sciences M&A 2023 trends."
23. Susan Kelly, "Illumina to part with Grail, ending battle with regulators," MedTech Dive, accessed 3 April 2024.
24. Elise Reuter, "Medtronic scraps plans to buy insulin patch-pump maker EOFlow," MedTech Dive, 7 December 2023.
25. Deloitte, "Life sciences M&A 2023 trends."
26. Deloitte, "Life sciences and Health Care Quarterly Update," Q4 2023.
27. Vito Sperduto, "Sponsors can operate in high-rates environments. It's a very resilient asset class.," RBC Capital Markets, 29 August 2023.
28. Madeline Shi, "Meet the 5 most active PE investors in life sciences."
29. Madeline Shi, "Meet the 5 most active PE investors in life sciences."
30. Deloitte, "Life sciences M&A 2023 trends."
31. Eva Mathews, "EQT to take UK's Dechra Pharma private in about \$6 bln deal," Reuters, 2 June 2023.
32. Loukia Gyftopoulou, "Private Equity's Hunt for Funds Is Pushing Firms to Middlemen," Bloomberg, 19 December 2023.
33. Rich Croghan, "Life Sciences Industry Market and Transaction Trends Update," Moss Adams, 21 December 2023.
34. Ben Fidler, "Arch, a prolific biotech creator, is raising \$3B for startup investing," BioPharma Dive, 2 February 2024.
35. Ibid.
36. Ben Fidler, "Biotech IPOs are the industry's lifeblood. Track how they're performing here.," BioPharma Dive, 1 April 2024.
37. Ibid.
38. Gwendolyn Wu, "Gene editing biotech Metagenomi pulls off nearly \$94M IPO," BioPharma Dive, 8 February 2024.
39. Annalee Armstrong, "Biotech bankruptcies hit 10-year peak in 2023," Fierce Biotech, 12 February 2024.
40. Ibid.
41. Ibid.
42. "Big Pharma Partnerships in 2023: A Comprehensive Overview," Maven Bio Research, 19 January 2024.
43. Deloitte, "Life sciences M&A 2023 trends."
44. "Verge and AZ Ink Potential \$840M Drug Discovery Deal," Inside Precision Medicine, 8 September 2023.

45. Ibid.
46. AbbVie "AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies," press release, 5 December 2023.
47. Raveena Bhambra, "Top 20 biopharma deals of 2023."
48. "Big Pharma Partnerships in 2023: A Comprehensive Overview," Maven Bio Research, 19 January 2024.
49. Raveena Bhambra, "Top 20 biopharma deals of 2023."
50. "Navigating Uncertainty 2023 M&A Trends Survey," Deloitte, 2023.
51. Annalee Armstrong, "Biotech bankruptcies hit 10-year peak in 2023," Fierce Biotech, 12 February 2024.
52. Solomon Slim, "Themes from BIO Europe," Evaluate, 17 November 2023.
53. Deloitte, "Regulatory realities amid M&A momentum," 2021.
54. Calliditas Therapeutics, "Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore," press release, 10 June 2019.
55. Nicola Moore, "Why is it so difficult for some cultures to say No?," LinkedIn, 2 January 2019.
56. Margaret Anderson, "Unlocking the potential of biomedical innovation: The crucial role the government and partnerships play in accelerating progress," Deloitte, 23 May 2023.
57. Ibid.
58. Ibid.
59. Ibid.
60. Ibid.
61. "Medtech Report," PitchBook, 28 November 2023.
62. Rich Croghan, "Life Sciences Industry Market and Transaction Trends Update," Moss Adams, 21 December 2023.
63. "Medtech Report," PitchBook.
64. Nick Paul Taylor, "Roundup: Medtech M&A slump continues but analysts predict uptick in 2024," MedTech Dive, accessed 3 April 2024.
65. Ibid.
66. Susan Kelly, "Medtronic to chase Boston Scientific, Abbott in left atrial appendage closure market," MedTech Dive, 28 November 2023.
67. Susan Kelly, "Intuitive's venture capital arm launches second investment fund," MedTech Dive, 5 December 2023.
68. "How We Invest @ JJDC," Johnson & Johnson Innovation, 2023.
69. "Johnson & Johnson Development Corporation," Crunchbase, 2024.
70. Susan Kelly, "Intuitive's venture capital arm launches second investment fund,"
71. Julie Bishop, "Intuitive Ventures Closes \$150 Million Fund II to Continue Investment in Startups Reimagining Minimally Invasive Care," Business Wire, 4 December 2023.
72. Iain Macmillan, "The path to thrive: M&A strategies for a brave new world," Deloitte, 2023.
73. Deloitte, "New year, new opportunities: M&A life sciences trends," 2024.
74. "Biden-Harris Administration Designates 31 Tech Hubs Across America," U.S. Economic Development Administration, 23 October 2023.
75. Jeanette Miriam Lorenz, "How quantum computing could be helpful for medical diagnostics," Fraunhofer, 7 July 2021.
76. "Minister Boissonnault announces federal investment to support Alberta's health technology sector," Government of Canada, 19 December 2023.
77. "Multi-million-pound funding boost for medical device innovation in Scotland," Medical Plastics News, 14 December 2023.
78. Michelle Moore, "NHS to receive \$26.7m to fund AI," Medical Device Network, 26 June 2023.
79. "Australia invests \$50 M into BioMedTech Incubator programme," BioSpectrum Asia, 23 March 2023.
80. Melanie Senior, "Cancer-targeting antibody-drug conjugates drive dealmaking frenzy," Nature Biotechnology volume 42 (2024), pp. 362–66.
81. Fraiser Kansteiner, "Daiichi Sankyo plots €1B expansion to beef up antibody-drug conjugate production in Germany," Fierce Pharma, 20 February 2024.
82. Melanie Senior, "Cancer-targeting antibody-drug conjugates drive dealmaking frenzy."

83. Ibid.
84. Ibid.
85. Ibid.
86. Angus Liu, "JPM24: As cancer players jump head-first into ADC field, Novartis CEO explains how he's resisted the temptation," Fierce Pharma, 8 January 2024.
87. Ibid.
88. Berkeley Lovelace Jr., "What to know about Zepbound, Eli Lilly's new weight loss drug," NBC Health, 9 November 2023.
89. "Market capitalization of Novo Nordisk (NVO)," CompaniesMarketCap, 2024.
90. "Market capitalization of Eli Lilly (LLY)," CompaniesMarketCap, 2024.
91. "Obesity Drugs Boost Pharma's Growth Outlook," Morgan Stanley, 6 September 2023.
92. "The increase in appetite for obesity drugs," J.P. Morgan, 29 November 2023.
93. Lisa Jarvis, "Obesity medicine's foggy future is getting clearer," Medical Xpress, 12 February 2024.
94. "The increase in appetite for obesity drugs," JPMorgan Chase, 29 November 2023.
95. Jennifer Couzin-Frankel, "2023 Breakthrough of the Year," American Association for the Advancement of Science, 14 December 2023.
96. Walter Beckwith, "Science's 2023 Breakthrough: GLP-1 Agonists Show Promise Against Obesity-Associated Disease," American Association for the Advancement of Science, 15 December 2023.
97. Kyle LaHucik, "Lilly partners with startup Fauna Bio to see if a squirrel's hibernation could lead to new obesity drugs," Endpoints News, 21 December 2023.
98. Associated Press, "Medicare won't pay for new weight-loss drugs, putting them out of reach for older Americans," Fast Company, 28 December 2023.
99. George Hampton, "Europe's lessons for the U.S. on how to cover weight loss drugs," STAT, 14 December 2023.
100. Associated Press, "Medicare won't pay for new weight-loss drugs, putting them out of reach for older Americans," Fast Company, 28 December 2023.
101. George Van Antwerp, "Growth of GLP-1s has implications for multiple stakeholders."
102. George Hampton, "Europe's lessons for the U.S. on how to cover weight loss drugs," STAT, 14 December 2023.
103. Ibid.
104. Irena Maragkou, "Biotechs ride obesity drug wave with novel approaches that go beyond GLP-1RAs," MSN, 15 February 2024.
105. Annika Kim Constantino, "The weight loss drug boom isn't over yet — here's what to expect in the year ahead," CNBC, 17 December 2023.
106. Reuters, "Roche joins race for obesity drugs with \$2.7 billion Carmot deal," accessed 3 April 2024.
107. Irena Maragkou, "Biotechs ride obesity drug wave with novel approaches that go beyond GLP-1RAs," MSN, 15 February 2024.
108. Jacob Robbins, "Weight loss startups ride the Ozempic, Wegovy wave," PitchBook, 16 October 2023.
109. Deloitte, "Life sciences M&A 2023 trends," 2024.



About Deloitte's Global Life Sciences Sector Group

Together, advancing the business of science

Creating a health care ecosystem that provides quality, accessible care for all takes innovative leaders. Challenging the status quo requires guidance from a trusted team equally committed to health equity and transformation. Deloitte Health Care stands alongside those who stand for better, improving individual lives and the health of society. We help redefine the care journey by engineering digital strategies based on our deep experience and insights. We help accelerate action and create connections that empower a digitally enabled, equitable future of health.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms, and their related entities (collectively, the "Deloitte organization"). DTTL (also referred to as "Deloitte Global") and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

Deloitte provides industry-leading audit and assurance, tax and legal, consulting, financial advisory, and risk advisory services to nearly 90% of the Fortune Global 500® and thousands of private companies. Our professionals deliver measurable and lasting results that help reinforce public trust in capital markets, enable clients to transform and thrive, and lead the way toward a stronger economy, a more equitable society, and a sustainable world. Building on its 175-plus year history, Deloitte spans more than 150 countries and territories. Learn how Deloitte's approximately 415,000 people worldwide make an impact that matters at www.deloitte.com.

This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms or their related entities (collectively, the "Deloitte organization") is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.

No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and the unrelated entities, are legally separate and independent entities.